SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read More
Tag: Jardiance
Heart failure med Jardiance scores MHRA approval
Marketing authorisation covers treatment of heart failure with reduced ejection fraction
Read More
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients
Read More
FDA dismisses Jardiance for type I diabetes
The decision follows an FDA panel vote last November recommending against the approval of the drug.
Read More
Jardiance bags FDA Fast Track designation
The decision follows a Jardiance Fast Track designation which was granted by the FDA in July 2019 for the risk of cardiovascular death.
Read More
Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
Type II diabetes costs the NHS £8.8 billion a year.
Read More
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Read More
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
Read More
BI, Lilly expand Jardiance programme in heart failure
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
Read More
FDA allows cardiovascular death reduction claim for Jardiance
In a huge boon for Lilly and Boehringer Ingelheim, US regulators have expanded the scope of diabetes drug Jardiance to include a reduction in the risk of cardiovascular death patients with type II forms of the condition and cardiovascular disease.
Read More
NICE backs three medicines for type 2 diabetes
Cost regulators for the NHS in England and Wales are backing the use of three monotherapies to treat patients with diabetes type 2: Janssen’s Invokana, AstraZeneca’s Forxiga and Boehringer Ingelheim/Lilly’s Jardiance.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
